Anthrax Lethal Factor Monoclonal Antibody (5F502.2), Invitrogen™

Mouse Monoclonal Antibody

Supplier:  Thermo Scientific MA141075

Catalog No. 01-676-460

Description

Suggested positive control: recombinant protein.

Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) and capillary morphogenesis protein 2 (CMG2), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm. LF is the primary toxin of anthrax and functions as a highly specific protease that cleaves members of the mitogen-activated protein kinase kinase (MAPKK) family near their amino terminus, interfering with MAPK signaling and inducing apoptosis.

Specifications

• Antigen: Anthrax Lethal Factor
• Classification: Monoclonal
• Concentration: 0.5 mg/mL
• Formulation: PBS with 0.05% BSA and 0.05% sodium azide
• Host Species: Mouse
• Purification Method: Protein G
• Regulatory Status: RUO
• Target Species: Bacteria
• Product Type: Antibody
• Isotype: IgG1 κ

• Applications: Western Blot
• Clone: 5F502.2
• Conjugate: Unconjugated
• Gene Alias: Anthrax LF
• Immunogen: Synthetic peptide corresponding to residues 779-792 of the anthrax LF protein.
• Quantity: 100 μg
• Primary or Secondary: Primary
• Content And Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
• Form: Liquid

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov